Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months.

Primary objective:

To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi pasteur.

Secondary objective:

To describe the safety of vaccination in all subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

NCT00621764

Japanese Encephalitis Hepatitis A

COMPLETED PHASE2

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

NCT01092507

Encephalitis Japanese Encephalitis

COMPLETED PHASE3

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

NCT01001988

Encephalitis Japanese Encephalitis

COMPLETED PHASE3

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

NCT02602652

Japanese Encephalitis

COMPLETED NA

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

NCT02526550

Encephalitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase III trial in toddlers in Thailand and the Philippines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Japanese Encephalitis Hepatitis A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JE-CV GPO MBP (Lot 1)

Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.

Group Type EXPERIMENTAL

Japanese encephalitis vaccine

Intervention Type BIOLOGICAL

0.5 mL, Subcutaneous

JE-CV GPO MBP (Lot 2)

Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.

Group Type EXPERIMENTAL

Japanese encephalitis vaccine

Intervention Type BIOLOGICAL

0.5 mL, Subcutaneous

JE-CV GPO MBP (Lot 3)

Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.

Group Type EXPERIMENTAL

Japanese encephalitis vaccine

Intervention Type BIOLOGICAL

0.5 mL, Subcutaneous

JE-CV WRAIR (Group 4)

Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)

Group Type ACTIVE_COMPARATOR

Japanese encephalitis vaccine (Acambis)

Intervention Type BIOLOGICAL

0.5 mL, Subcutaneous

Hepatitis A (Group 5)

Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine

Group Type SHAM_COMPARATOR

Hepatitis A vaccine

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Japanese encephalitis vaccine

0.5 mL, Subcutaneous

Intervention Type BIOLOGICAL

Japanese encephalitis vaccine

0.5 mL, Subcutaneous

Intervention Type BIOLOGICAL

Japanese encephalitis vaccine

0.5 mL, Subcutaneous

Intervention Type BIOLOGICAL

Japanese encephalitis vaccine (Acambis)

0.5 mL, Subcutaneous

Intervention Type BIOLOGICAL

Hepatitis A vaccine

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ChimeriVax™-JE ChimeriVax™-JE ChimeriVax™-JE Avaxim® 80U Pediatric

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 12 to 18 months on the day of inclusion.
* In good general health, without significant medical history.
* Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations.
* Subject and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.
* Completion of vaccinations according to the national immunization schedule.

Exclusion Criteria

* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.
* Planned participation in another clinical trial during the present trial period.
* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances.
* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.
* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response.
* Administration of any anti-viral within 2 months preceding V01.
* History of central nervous system disorder or disease, including seizures.
* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.
* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
* Planned receipt of any vaccine in the 4 weeks following any trial vaccination.
* Personal human immunodeficiency virus seropositivity in the blood sample taken at screening.
* Receipt of any JE vaccine or hepatitis A vaccine.
* Previous vaccination against flavivirus disease.
* History of flavivirus infection (confirmed either clinically, serologically or microbiologically)
* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination.
* Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.

Minimum Eligible Age

12 Months

Maximum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes